Older patients with acute myelogenous leukemia (AML) are at increased risk for mortality and morbidity. While allogeneic stem cell transplantation may provide cure in some patients, many still relapse after transplant and are then left with limited therapeutic options and poor survival. Moreover, the quality of the end-of-life care for these patients has not been previously reported. We describe here the end-of-life experience of a cohort of 72 older patients with AML who relapsed after first allogeneic stem cell transplant at our dedicated cancer center. Despite a median overall survival of only 4 months, we find a high level of primary palliative care delivered by transplant/leukemia physicians through goals of care discussions and/or advanced care planning and provide evidence for high-quality end-of-life care outcomes, often with concurrent diseasedirected therapy. Our results compare favorably with end-of-life care outcomes reported for older AML patients, including those who did not undergo transplant. Given the poor prognosis and unique underlying vulnerabilities in this high-risk patient population, incorporating timely advanced care planning and palliative care delivery while exploring available salvage options may further improve end-of-life care outcomes.
Introduction
Allogeneic hematopoietic stem cell transplantation (HCT) is a potential curative treatment for the majority of patients with acute myelogenous leukemia (AML) [1, 2] . The development of reduced-intensity conditioning regimens and improved supportive care has led to an increased number of older patients undergoing HCT, with encouraging survival outcomes and acceptable treatment-related toxicities [3] [4] [5] [6] . However, relapse after HCT remains a significant challenge for older patients due to higher risk disease, increased comorbidities, and delayed immune reconstitution after transplant [7, 8] . Long-term survival after relapse has only been observed in those with a long relapse-free interval, good performance status, and treatments with cellular immunotherapy such as donor lymphocyte infusion (DLI) or second HCT [9] [10] [11] . As a result, outcomes of AML patients relapsing after HCT are generally poor with most patients dying of infections and/or treatment complications within 6 months [9] [10] [11] [12] .
Recent studies have highlighted suboptimal end-of-life care for older AML patients with intense healthcare resource utilization [13, 14] . El-Jawahri et al. described endof-life experiences of 330 older AML patients and found that regardless of treatment intensity, there was an extensive healthcare resource utilization and only a minority received palliative care (16.2%) or hospice (23.1%) services [13] . Subsequently, Wang et al. utilized the Surveillance, Epidemiology, and End Results (SEER) Medicare linked database to examine end-of-life care in a nation-wide cohort of 13,156 older AML patients. They found that hospice care after AML diagnosis increased from 31.3% in 1999 to 56.4% in 2012, although most of this increase in enrollment occurred in the last 7 days of life. There was also a significant increase in chemotherapy use in the last 14 days of life from 7.7% in 1999 to 18 .8% in 2012 [14] . None of these studies, however, have focused on the experience of AML patients relapsing after HCT. Moreover, the relative contribution of primary palliative care, defined as basic palliative care such as basic pain management and routine goals of care discussion delivered by the primary oncologist, versus the subspecialty level, interdisciplinary palliative care, has not been examined [15, 16] . We report here the quality of the end-of-life care in a cohort of older AML patients who relapsed after an HCT at our institution, in the context of their post-relapse treatment and survival.
Materials and methods

Patients and outcomes
This retrospective study included 72 consecutive patients age 60 or older, who received an HCT at our institution for the treatment of AML between January 2001 and December 2017, and subsequently relapsed or had progression of their disease. A waiver of authorization for this retrospective review was obtained from the Institutional Review and Privacy Board. Pathologic diagnosis for AML was confirmed for each patient at the Memorial Sloan Kettering Cancer Center (MSKCC). Routine eligibility criteria for HCT included availability of an Human Leukocyte Antigen (HLA)-identical or single antigen mismatched adult donor or umbilical cord blood grafts; absence of active fulminant infection; and lack of serious coexisting comorbidities such as reduced left ventricular ejection fraction <35%, advanced liver cirrhosis, or a corrected pulmonary diffusing capacity of the lung for carbon monoxide <35%, which would preclude administration of cytoreductive regimens. Standard post-transplant care and disease monitoring followed institutional guidelines. Initial hematological relapse was defined by the 2017 European Leukemia Net guideline and included: new appearance of bone marrow blasts ≥5%; or reappearance of blasts in the blood; or the development of extramedullary disease [17] . The definition of initial subclinical relapse is the detection of disease by sensitive methods such as multicolor flow cytometry, cytogenetics, or molecular technique preceding overt hematological relapse.
We reviewed the medical records and the institutional database for these patients. Documented goals of care discussion, advanced care planning, and Do-Not-Resuscitate (DNR) order in the medical record were recorded. The primary endpoint of the study is the quality of the end-oflife care measured by three commonly accepted, positive indicators endorsed by multiple national organizations: hospice enrollment at the end-of-life; no chemotherapy use within 14 days of death; and no hospitalization/intensive care unit (ICU) admission within 30 days of death [14, 18, 19] . In addition, we examined potential independent predictors of quality end-of-life care including demographic variables of age, gender, ethnicity, marital status, and preexisting psychiatric diagnosis; clinical variables of disease type, HCT-Comorbidity Index (HCT-CI), revised disease risk index, and routine transplant characteristics; and relapse variables of disease-free interval, relapse type, Karnofsky Performance Status (KPS) at relapse, and treatment after relapse. Post-relapse survival is a time-to-event outcome started from the date of relapse as defined above.
Statistical analysis
Analyses were performed with a data cutoff date of 30 April 2018. We used descriptive statistics to characterize binary end-of-life care outcomes. The associations between standard demographic, clinical, and relapse characteristics with quality end-of-life care outcomes were compared using Fisher's exact test and t-test as appropriate. The probabilities of survival at selected time points and its univariate association with transplant variables were estimated using the Kaplan-Meier method and the log-rank test. Univariate and multivariate comparisons of binary quality end-of-life care outcomes across standard demographic, clinical, relapse, and treatment characteristics were evaluated using the logistic regression model. All statistical analyses were performed and graphed in either STATA IC 15.1 or Microsoft Excel. Table 1 summarizes patient and transplant characteristics. In total, 257 AML patients of age 60 and above underwent first HCT at our institution from 2001 to 2017, and their demographics are similar to the general allogeneic HCT patient population. By 30 April 2018, 72 patients (28%) had relapsed or experienced progression of their disease. Following relapse, all patients had follow-up visits with their transplant and/or leukemia physicians. The median time to relapse was 6.5 months and the majority (81%) first presented with hematological (clinical) relapse. The rest were sub-clinical relapses initially detected by multicolor flow cytometry, cytogenetic, or molecular methods. Most patients (89%) had a KPS of 70 or higher at the time of relapse. All relapses were detected by their transplant physicians. Table 1 also summarizes the outcomes after relapse. Twenty-one percent of patients received supportive care only, which included red blood cell and platelet transfusion, antibiotics for infection, or hydration support as needed. Fifty-six percent received low-intensity treatment, which included hypomethylating agents, oral targeted small molecular drugs, phase I clinical trials, and/or DLIs, and 23% received high-intensity treatment comprised of reinduction chemotherapy, including five patients who underwent a second HCT. The median post-relapse overall survival (OS) was 134 days and the one-year survival probability was 20% (95% CI, 12-30). Only three patients have remained alive with a median follow-up of 2 years, and patients who had received either low-or high-intensity treatment after relapse lived longer than patients who received supportive care only (Fig. 1 , p < 0.001). There was no statistical difference in survival between patients who had received either low-or high-intensity treatment (Fig. 1) . In the univariate analysis, male gender, relapse interval of more than 1 year, KPS ≥70, and receiving any treatment post relapse were associated with increased survival. Among the three survivors, two had received a second HCT and one had received DLI.
Results
Patients and transplant characteristics
Treatment and survival after relapse
End-of-life care characteristics Table 2 summarizes the end-of-life care of our cohort of patients who have died. Twelve patients did not receive end-of-life care at our institution and were excluded. The remaining 57 patients shared similar characteristics to the overall cohort of patients. Almost all patients (96%) had a documented goal of care discussion and/or advanced care planning with their primary physicians (either transplant HCT-CI hematopoietic cell transplant-comorbidity index, NMA nonmyeloablative conditioning, RIC reduced intensity conditioning, KPS Karnofsky performance score, GvHD graft versus host disease, HMA hypomethylating agents, DLI donor lymphocyte infusion and/or leukemia physicians) at a median of 13 days after relapse. Thirty-two percent of patients had received a subspecialty palliative care consultation, all as inpatients, at a median of 24.5 days after relapse. Only 7% of the patients had received any chemotherapy in the last 2 weeks of life, although six patients were on targeted oral agents for parts of their last 2 weeks of life. Overall, 84% of patients who died were admitted to the hospital within 30 days of death and 33% were admitted to the ICU. Overall, 77% of the patients who died had a documented DNR order. Regarding the place of death, 58% of patients died in the hospital with the remainder either at home or an inpatient hospice. The overall hospice enrollment rate was 40% with a median of 9 days spent in the hospice.
Quality of the end-of-life care
We assessed the overall presence of three well-established, high-quality end-of-life care indicators in our cohort of patients: hospice enrollment at the end-of-life; no chemotherapy use in the last 14 days of life; and no hospitalization/ICU admission within 30 days before death. Ninety-three percent of patients had at least one highquality end-of-life care indicator, and 49% had at least two indicators. Only four patients did not have any of the three high-quality end-of-life care indicators. No patient, transplant, or relapse-related characteristics predicted any highquality end-of-life indicators by either univariate or multivariate analyses (data not shown).
The subspecialty palliative care service at our institution has traditionally been a multidisciplinary, interprofessional team composed of physicians, nurse practitioners, a social worker, a chaplain, and a clinical pharmacist. A subspecialty palliative care consultation after relapse was not associated with increased hospice enrollment, decreased end-oflife chemotherapy use, or decreased hospitalization or ICU admission at the end-of-life (data not shown). When examined by time periods of relapse, the use of subspecialty palliative care consultation had increased from 12% in 2000 to 29% from 2011 to 2014 and to 53% by year 2015-17 (Fig. 2, p = 0.029) . In contrast, the use of hospice service, chemotherapy use at the end-of-life, and hospitalization/ ICU admission at the end-of-life remained constant throughout these time periods (Fig. 2) . Figure 3 depicts the performance of these quality end-of-life care indicators according to types of treatment received, and no significant statistical difference was found among them.
Discussion
AML in the elderly is an unmet medical need from both therapeutic and end-of-life care perspectives [7, 13, 14, 20] . For patients who relapse after an HCT, the situation is even more challenging regarding therapeutic options, and their end-of-life experience has remained largely unexplored. In this study, we recapitulate the poor survival in this vulnerable patient population (median OS of 4 months) and establish the baseline end-of-life care outcomes for these patients. We find that patients who have received disease- HMA hypomethylating agents, DLI donor lymphocyte infusion, GOC goals-of-care, ACP advanced care planning, ICU intensive care unit directed treatment post relapse lived longer, although this is likely confounded by patient selection bias from, for example, KPS and clinical trial availability, and their symptom burden and quality of life at the end-of-life remained unknown. Importantly, we have identified many characteristics associated with high-quality end-of-life care, including documented goals of care discussion and/or advanced care planning (96%); no chemotherapy in the last 14 days of life (93%); a palliative care consultation after relapse (32%); and hospice enrollment (40%) with a median hospice length of stay of 9 days. Our results compare favorably with aforementioned findings on end-of-life care in older AML patients in which only 23% patients enrolled in hospice [13] , and almost 19% patients received chemotherapy in the last 14 days of life [14] , and with reports on palliative care provision for these patients at the end-of-life [21] [22] [23] . We do note, however, that our hospitalization/ICU admission rates at the end-of-life remains high at 84% and 33%, respectively, similar to 89% and 36%, respectively, from a previous study [13] . In addition, the hospice enrollment rate at the end-of-life still lags behind older solid tumor and noncancer patients except for heart failure patients [24, 25] . Finally, despite increased subspecialty palliative care consultation over time, other quality end-of-life indicators have not changed significantly over time. These are obvious areas of improvement.
Goals of care discussion and/or advanced care planning constitute an essential component of primary palliative care delivered by oncologists [15, 16] . It is likely that our high rate of goals of care discussion and/or advanced care planning has contributed to quality end-of-life outcomes. First, our institution is a dedicated academic cancer center with a well-established subspecialty palliative care service and other subspecialty consult services such as psychiatry and integrative medicine. It is likely that the post-relapse care delivered in this multidisciplinary setting helps improve the quality of the end-of-life care such as reduction of chemotherapy use at the end-of-life. On the other hand, indicators such as hospitalization/ICU admission may not be prioritized in such a setting. Second, the close relationship between the transplant service and the leukemia services likely facilitates the transition of care. This is supported by the fact that most of the documented goals of care discussions and/or advanced care planning were conducted by both services and occurred early after the relapse. Finally, these patients have typically been made aware of the grave prognosis associated with relapse after HCT throughout the transplant process, and the prognostic knowledge may help overcome perhaps the single most important patient-related barrier to high-quality end-of-life care in blood cancer-unrealistic expectations [26] . It is likely that the intense longitudinal relationship formed between the patient and the transplant/leukemia physician helps facilitate the important prognostic discussion and the delivery of primary palliative care.
We are unable to identify predictors of high-quality endof-life care in our cohort of patients, presumably due to small sample size. Interestingly, while the use of interprofessional, subspecialty palliative care service after relapse has significantly increased over the years, quality end-of-life care indicators have remained constant at our institution. It is likely that there are other barriers to quality We did not identify significant changes in hospice use, chemotherapy in the last 14 days, hospitalization in the last 30 days, and ICU admission in the last 30 days over different treatments after relapse end-of-life care. For example, transfusion requirement, which is not covered by traditional hospice service, may have prevented patients from receiving hospice care or have led to hospitalizations at the end-of-life [27, 28] . In addition, important benefits of subspecialty palliative care consultation such as expert symptom management, psychosocial support, and caregiver support were not readily available for assessment in this retrospective study. Finally, it is also possible that primary palliative care delivered by transplant/leukemia physicians has been driving end-of-life outcomes for these patients. We have also found that even for patients who have received supportive care only after relapse, their use of hospice service and hospitalization/ICU admission rate at the end-of-life is not significantly different from patients who have received lowor high-intensity treatment, again suggesting the presence of additional barriers such as transfusion requirement. Our study has several limitations. First, it is a retrospective, single institution study with a relatively small sample size, which could potentially contain patient selection bias. Second, the small sample size limits our evaluation of patient, transplant, and relapse characteristics predicting quality end-of-life care outcomes. Third, we examined quality indicators of end-of-life outcomes but not patients' quality of life or symptom burden at the end-oflife, which was not readily available in this retrospective study. Fourth, specific contents of goals of care discussions and/or advanced care planning were not readily available, which precluded any qualitative, thematic analyses. Finally, as the study was conducted at a dedicated academic cancer center, the findings may not be applicable to other settings. Despite the above limitations, our study is the first to examine end-of-life care outcomes in AML patients relapsing after an HCT. Given the sudden shift in goals of care from curative to palliative, the transition of care from the transplant to the leukemia team, and the immunocompromised state post-transplant, these patients are more vulnerable and fragile, both medically and psychosocially, than typical AML patients, thus warranting aggressive supportive interventions.
Our study also complements the emerging literature on the integration of subspecialty palliative care in blood disorders and HCT [29] . Early integration of subspecialty palliative care during routine transplant care has been shown to reduce symptom burden, psychological distress, and decrease in quality of life after transplant [30, 31] . We demonstrate here a high rate of primary palliative care delivery by transplant/leukemia physicians and a high percentage of patients with quality end-of-life care indicators, while the impact of subspecialty palliative care service in this patient population remains to be determined. Considering these patients' poor prognosis and high symptom burden [22, 23] , early involvement of subspecialty palliative care service and ongoing collaboration with transplant/leukemia physicians may warrant prospective investigation.
